Wednesday, 7 January 2015

New drug combination for advanced breast cancer delays disease progression

A new multi-center phase II trial conducted at Mt. Sinai Hospital for patients with hormone-receptor-positive metastatic breast cancer has shown that  a combination of cancer drugs, bortezomib and fulvestrant vs. fulvestrant alone has "doubled the rate of survival at 12 months [14% to 28%] and reduced the chance of cancer progression overall."  According to Dr. Kerin Adelson, assistant professor of medical oncology at Yale Cancer Center and principle investigator for this study, the results from the drug combination are encouraging and should be further explored in other patient populations, including those afflicted with metastatic breast cancer.

To read more about this study, presented at the 2014 San Antonio  Breast Cancer Symposium, December 2014, click here.

No comments:

Post a Comment